Allogeneic Placental Pluripotent Cells
Human placental-derived mesenchymal-like stromal cells are a novel, culture-expanded mesenchymal-like cell population derived from healthy, full-term human placental tissue. These cells are plastic-adherent and undifferentiated in vitro and express pluripotency related genes. Mesenchymal-like stromal cells are genetically stable, displaying a normal diploid chromosome count, and a normal karyotype and exhibit normal senescence after prolonged culture periods. In vitro studies showed that these cells exhibit immune-modulatory properties – they suppress effector cell function, promote tolerogenic immune phenotype, and reduce pro-inflammatory cytokine secretion. Mesenchymal-like stromal cells also possess regenerative and pro-angiogenic properties demonstrated through the secretion of several mitogenic and angiogenic factors. In vivo, we have demonstrated immune-modulatory properties of mesenchymal-like stromal cells alleviate autoimmunity in encephalomyelitis (EAE) mouse model, and possess anti-inflammatory activity in rat perineural inflammation neuritis model, anti-fibrotic effect in mice lung fibrosis model and neuroprotection and pro-neurogenesis functions in rodent stroke models.
Both intravenous and intramuscular administration formulations of mesenchymal-like stromal cells have been developed and investigated in clinical studies in Crohn’s Disease, multiple sclerosis, rheumatoid arthritis, diabetic foot ulcers, and diabetic peripheral neuropathy.
The current lead therapeutic candidates APPL, namely Allogeneic Placental Pluripotent cells, are developed utilizing genetically modification, novel media/cultivation methods to achieve desired safety profile, pluripotency, and efficacy.